E.i. Dupont De Nemours and Company

The Dupont Merck Pharmaceutical Company

Dupont Pharmaceuticals Company

Paul E Aldrich

Gilbert H Berezin

John J Duncia

Michael Ernest Pierce

Bruce Ivor Dittmar

Robert J Chorvat

Paul Joseph Gilligan

Philip Ma

Richard A Earl

Argyrios Georgios Arvanitis

Carl Nicholas Hodge

Zelda Rakowitz Wasserman

Robert Scott Cheeseman

Rajagopal Bakthavatchalam

Philip Manos

James Peter Beck

Dimitri Emil Grigoriadis

Thomas E Christos

Allan E Nader

Paul John Krenitsky

Sang William Tam

Everett Latham Scholfield

1N-alkyl-n-arylpyrimidinamines and derivatives thereof

The present invention provides novel compounds, compounds and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems. The novel compounds provided by this invention are those of formula: ##STR1## wherein R.sup.1, R.sup.3, R.sup.4, R.sup.5, Z, Y, V, X, X', J, K, L, and M are as defined herein.

1N-alkyl-N-arylpyrimidinamines and derivatives thereof

Negative photoresists, and electronic devices comprising dielectric polyimide films resulting from such photoresists. The Photoresists comprise polyamic acids, which have been neutralized with tertiary amines containing double bonds of the acrylic family, the amines including acrylamines, alkylacrylamines such as for example methacrylamines, ethacrylamines, and the like. Also methods of making such amines in high purity.

Negative photoresists containing aminoacrylate salts

There are provided novel 1,4-dihydropyridine compounds possessing both calcium agonist and alpha.sub.1 -antagonist activity useful for treating congestive heart failure, pharmaceutical compositions containing them and methods of using these compounds to treat congestive heart failure in a mammal.

2-amino-1, 4-dihydropyridine derivatives with calcium agonist and

2-amino-1,4-dihydropyridine derivatives with calcium agonist and

Tetrazole intermediates useful to prepare antihypertensive compounds described in coassigned application U.S. Ser. No. 884,920, filed July 11, 1986, are described, these tetrazoles have the formula: ##STR1## wherein X.sup.1 and X.sup.2 are as described in the specification.

Tetrazole intermediates to antihypertensive compounds

Polyhalohydroxyisopropyl phenylalkanoic and phenylalkenoic acids, amides, and esters, such as methyl 2-methoxy-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzenepro panoate, are useful as antihypertensive agents.

Antihypertensive polyhalohydroxylisopropyl phenylalkanoic and

Polyfluorohydroxyisopropyl tricyclic carbostyrils, such as 2,3-dihydro-7-methyl-9-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl ]-5H-[1,4]thiazino[2,3,4-ij]-quinolin-5-one, useful as antihypertensive agents.

Antihypertensive polyfluoroisopropyl tricyclic carbostyrils

Polyfluorohydroxyisopropyl: -indolines, -tetrahydroquinolines, and -benzazepines, such a .alpha.,.alpha.-bis(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-6-methano l, useful as intermediates for antihypertensives.

Polyfluorohydroxyisopropyl-heterocyclic compounds

Polyfluorohydroxyisopropyl bicyclic and tricyclic carbostyrils, such as 1,2-dihydro-8-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-6-methy l-4H-pyrrolo-[3,2,1-ij]quinolin-7-one, useful as antihypertensive agents.

Antihypertensive polyfluorohydroxyisopropyl bicyclic and tricyclic

Hexafluorohydroxyisopropyl: -tetrahydroquinolines, -benzazepines, and -benzazocines, such as 2,3,4,5-tetrahydro-1-(1-oxopropyl)-.alpha.,.alpha.-bis(trifluoromethyl)-1H -1-benzazepine-7-methanol useful as antihypertensives.

Antihypertensive hexafluorohydroxyisopropyl benzazepines and benzazocines

This invention relates to a class of 1-tertiary-alkyl-3-(substituted thienyl)ureas and 1-tertiary-alkyl-3-(substituted thietyl)ureas that exhibit antihypertensive activity in warm-blooded animals. Representative compounds are 1-tert-butyl-3-(4,5-dihydro-3-thienyl)urea S,S-dioxide and 1-tert-butyl-3-(3-thietyl)urea S,S-dioxide.

1-Tertiary-alkyl-3-(substituted thienyl)ureas and

This invention relates to a class of 1-tertiary-alkyl-3-(substituted thienyl)ureas and 1-tertiary-alkyl-3-(substituted thietyl)ureas that exhibit antihypertensive activity in warm-blooded animals. Representative compounds are 1-tert-butyl-3-(4,5-dihydro-3-thienyl)urea S,S-dioxide and 1-tert-butyl-3-(3-thiethyl)urea S,S-dioxide.

Growing community of inventors

Wilmington, DE, United States of America

Paul E Aldrich